An update from Olema Pharmaceuticals ( (OLMA) ) is now available.
On March 5, 2025, Olema Pharmaceuticals announced the availability of a presentation for investors, highlighting their strategic priorities and clinical pipeline advancements. The company is actively accruing patients for pivotal Phase 3 trials of palazestrant, aiming for a potential commercial launch in 2027, and has announced a new collaboration with Novartis. These developments could significantly impact Olema’s market positioning and offer promising treatment options for breast cancer.
More about Olema Pharmaceuticals
Olema Pharmaceuticals is a leader in developing therapies for endocrine-driven cancers, focusing on advancing medicines for breast cancer and beyond. The company is headquartered in San Francisco, CA, with offices in Cambridge, MA, and has approximately 100 employees. Olema is working on establishing palazestrant as a best-in-class treatment for ER+/HER2- breast cancer and advancing the clinical development of OP-3136, a potential best-in-class KAT6 inhibitor for breast and other solid tumor cancers.
YTD Price Performance: -24.60%
Average Trading Volume: 1,181,945
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $287M
See more insights into OLMA stock on TipRanks’ Stock Analysis page.